Physician profile
John Ira Thurmond
NPI 1033151014
$14,920.77
in general payments reported to CMS, 2019-2025
63 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,872 · 2020: $2,102 · 2021: $2,692 · 2022: $2,365 · 2023: $1,947 · 2024: $2,286 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,575 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,574.56 |
| Education | $315.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.05 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,267.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,207.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,001.41 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $988.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $966.47 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $831.47 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $712.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $643.40 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $511.54 | 2019-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $448.55 | 2019-2023 | Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $370.88 | 2019-2024 | Trintellix |
| Esperion Therapeutics, INC. | $358.64 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $334.64 | 2021-2025 | |
| Allergan, INC. | $306.02 | 2019-2020 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thurmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.